Cargando…
Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study
Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and infected with variants different from those currently circulating. We conducted a retrospective study on patients with conf...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607194/ https://www.ncbi.nlm.nih.gov/pubmed/36298596 http://dx.doi.org/10.3390/vaccines10101731 |
_version_ | 1784818481553735680 |
---|---|
author | Gentile, Ivan Scotto, Riccardo Schiano Moriello, Nicola Pinchera, Biagio Villari, Riccardo Trucillo, Emilia Ametrano, Luigi Fusco, Ludovica Castaldo, Giuseppe Buonomo, Antonio Riccardo |
author_facet | Gentile, Ivan Scotto, Riccardo Schiano Moriello, Nicola Pinchera, Biagio Villari, Riccardo Trucillo, Emilia Ametrano, Luigi Fusco, Ludovica Castaldo, Giuseppe Buonomo, Antonio Riccardo |
author_sort | Gentile, Ivan |
collection | PubMed |
description | Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and infected with variants different from those currently circulating. We conducted a retrospective study on patients with confirmed SARS-CoV-2 infection treated with OAs during the omicron surge in Italy in order to provide real-life data on the efficacy and safety of OAs during the omicron surge of the COVID-19 pandemic. Among 257 patients, 56.8% received molnupiravir, while 43.2% received nirmatrelvir/ritonavir. Patients in the molnupiravir group were older, had a lower body mass index, and had a higher rate of chronic heart disease than those treated with nirmatrelvir/ritonavir. Three hospitalizations were recorded in the molnupiravir (2.1%) group and one in the nirmatrelvir/ritonavir (0.9%) group. One patient treated with molnupiravir died. The median time to negativity was 8 days in the nirmatrelvir/ritonavir group vs. 10 days in the molnupiravir group, p < 0.01. We recorded 37 ADRs (mainly dysgeusia, diarrhea, and nausea) in 31 individuals (12.1%). Only two patients (0.8%) treated with molnupiravir terminated treatment due to ADRs. In conclusion, in a population of mostly vaccinated patients treated with OAs, we observed a low rate of hospitalization, death, and adverse drug reactions. These rates were lower than those reported in pivotal trials. |
format | Online Article Text |
id | pubmed-9607194 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96071942022-10-28 Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study Gentile, Ivan Scotto, Riccardo Schiano Moriello, Nicola Pinchera, Biagio Villari, Riccardo Trucillo, Emilia Ametrano, Luigi Fusco, Ludovica Castaldo, Giuseppe Buonomo, Antonio Riccardo Vaccines (Basel) Article Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and infected with variants different from those currently circulating. We conducted a retrospective study on patients with confirmed SARS-CoV-2 infection treated with OAs during the omicron surge in Italy in order to provide real-life data on the efficacy and safety of OAs during the omicron surge of the COVID-19 pandemic. Among 257 patients, 56.8% received molnupiravir, while 43.2% received nirmatrelvir/ritonavir. Patients in the molnupiravir group were older, had a lower body mass index, and had a higher rate of chronic heart disease than those treated with nirmatrelvir/ritonavir. Three hospitalizations were recorded in the molnupiravir (2.1%) group and one in the nirmatrelvir/ritonavir (0.9%) group. One patient treated with molnupiravir died. The median time to negativity was 8 days in the nirmatrelvir/ritonavir group vs. 10 days in the molnupiravir group, p < 0.01. We recorded 37 ADRs (mainly dysgeusia, diarrhea, and nausea) in 31 individuals (12.1%). Only two patients (0.8%) treated with molnupiravir terminated treatment due to ADRs. In conclusion, in a population of mostly vaccinated patients treated with OAs, we observed a low rate of hospitalization, death, and adverse drug reactions. These rates were lower than those reported in pivotal trials. MDPI 2022-10-17 /pmc/articles/PMC9607194/ /pubmed/36298596 http://dx.doi.org/10.3390/vaccines10101731 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gentile, Ivan Scotto, Riccardo Schiano Moriello, Nicola Pinchera, Biagio Villari, Riccardo Trucillo, Emilia Ametrano, Luigi Fusco, Ludovica Castaldo, Giuseppe Buonomo, Antonio Riccardo Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study |
title | Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study |
title_full | Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study |
title_fullStr | Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study |
title_full_unstemmed | Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study |
title_short | Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study |
title_sort | nirmatrelvir/ritonavir and molnupiravir in the treatment of mild/moderate covid-19: results of a real-life study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607194/ https://www.ncbi.nlm.nih.gov/pubmed/36298596 http://dx.doi.org/10.3390/vaccines10101731 |
work_keys_str_mv | AT gentileivan nirmatrelvirritonavirandmolnupiravirinthetreatmentofmildmoderatecovid19resultsofareallifestudy AT scottoriccardo nirmatrelvirritonavirandmolnupiravirinthetreatmentofmildmoderatecovid19resultsofareallifestudy AT schianomoriellonicola nirmatrelvirritonavirandmolnupiravirinthetreatmentofmildmoderatecovid19resultsofareallifestudy AT pincherabiagio nirmatrelvirritonavirandmolnupiravirinthetreatmentofmildmoderatecovid19resultsofareallifestudy AT villaririccardo nirmatrelvirritonavirandmolnupiravirinthetreatmentofmildmoderatecovid19resultsofareallifestudy AT trucilloemilia nirmatrelvirritonavirandmolnupiravirinthetreatmentofmildmoderatecovid19resultsofareallifestudy AT ametranoluigi nirmatrelvirritonavirandmolnupiravirinthetreatmentofmildmoderatecovid19resultsofareallifestudy AT fuscoludovica nirmatrelvirritonavirandmolnupiravirinthetreatmentofmildmoderatecovid19resultsofareallifestudy AT castaldogiuseppe nirmatrelvirritonavirandmolnupiravirinthetreatmentofmildmoderatecovid19resultsofareallifestudy AT buonomoantonioriccardo nirmatrelvirritonavirandmolnupiravirinthetreatmentofmildmoderatecovid19resultsofareallifestudy AT nirmatrelvirritonavirandmolnupiravirinthetreatmentofmildmoderatecovid19resultsofareallifestudy |